CF PharmTech (HKG:2652) said its inhalation formulation production base in Suzhou passed a good manufacturing practice inspection conducted by the drug regulator of a member country of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme, according to a Thursday Hong Kong bourse filing.
The inspection covered the facility's production management and quality control systems, premises, equipment, data integrity, and computerized systems.
Shares of the pharmaceutical firm were up over 1% in Friday morning trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments